BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 28681984)

  • 1. BRD4 promotes gastric cancer progression through the transcriptional and epigenetic regulation of c-MYC.
    Ba M; Long H; Yan Z; Wang S; Wu Y; Tu Y; Gong Y; Cui S
    J Cell Biochem; 2018 Jan; 119(1):973-982. PubMed ID: 28681984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma.
    Sengupta D; Kannan A; Kern M; Moreno MA; Vural E; Stack B; Suen JY; Tackett AJ; Gao L
    Epigenetics; 2015; 10(6):460-6. PubMed ID: 25941994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of BRD4 suppresses tumor growth in prostate cancer via the enhancement of FOXO1 expression.
    Tan Y; Wang L; Du Y; Liu X; Chen Z; Weng X; Guo J; Chen H; Wang M; Wang X
    Int J Oncol; 2018 Dec; 53(6):2503-2517. PubMed ID: 30272279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PRMT5-dependent transcriptional repression of c-Myc target genes promotes gastric cancer progression.
    Liu M; Yao B; Gui T; Guo C; Wu X; Li J; Ma L; Deng Y; Xu P; Wang Y; Yang D; Li Q; Zeng X; Li X; Hu R; Ge J; Yu Z; Chen Y; Chen B; Ju J; Zhao Q
    Theranostics; 2020; 10(10):4437-4452. PubMed ID: 32292506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression.
    Li GQ; Guo WZ; Zhang Y; Seng JJ; Zhang HP; Ma XX; Zhang G; Li J; Yan B; Tang HW; Li SS; Wang LD; Zhang SJ
    Oncotarget; 2016 Jan; 7(3):2462-74. PubMed ID: 26575167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compensatory RNA polymerase 2 loading determines the efficacy and transcriptional selectivity of JQ1 in Myc-driven tumors.
    Donato E; Croci O; Sabò A; Muller H; Morelli MJ; Pelizzola M; Campaner S
    Leukemia; 2017 Feb; 31(2):479-490. PubMed ID: 27443262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRD4 Regulates EZH2 Transcription through Upregulation of C-MYC and Represents a Novel Therapeutic Target in Bladder Cancer.
    Wu X; Liu D; Tao D; Xiang W; Xiao X; Wang M; Wang L; Luo G; Li Y; Zeng F; Jiang G
    Mol Cancer Ther; 2016 May; 15(5):1029-42. PubMed ID: 26939702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JQ1 and PI3K inhibition synergistically reduce salivary adenoid cystic carcinoma malignancy by targeting the c-Myc and EGFR signaling pathways.
    Liu X; Wu H; Huang P; Zhang F
    J Oral Pathol Med; 2019 Jan; 48(1):43-51. PubMed ID: 30269363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human ZNF312b oncogene is regulated by Sp1 binding to its promoter region through DNA demethylation and histone acetylation in gastric cancer.
    Song IS; Ha GH; Kim JM; Jeong SY; Lee HC; Kim YS; Kim YJ; Kwon TK; Kim NS
    Int J Cancer; 2011 Nov; 129(9):2124-33. PubMed ID: 21170990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOXO6 promotes gastric cancer cell tumorigenicity via upregulation of C-myc.
    Qinyu L; Long C; Zhen-dong D; Min-min S; Wei-ze W; Wei-ping Y; Cheng-hong P
    FEBS Lett; 2013 Jul; 587(14):2105-11. PubMed ID: 23714368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.
    Zuber J; Shi J; Wang E; Rappaport AR; Herrmann H; Sison EA; Magoon D; Qi J; Blatt K; Wunderlich M; Taylor MJ; Johns C; Chicas A; Mulloy JC; Kogan SC; Brown P; Valent P; Bradner JE; Lowe SW; Vakoc CR
    Nature; 2011 Aug; 478(7370):524-8. PubMed ID: 21814200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers.
    Bihani T; Ezell SA; Ladd B; Grosskurth SE; Mazzola AM; Pietras M; Reimer C; Zinda M; Fawell S; D'Cruz CM
    Oncotarget; 2015 Feb; 6(4):2407-20. PubMed ID: 25537515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRD4 Promotes Gastric Cancer Progression and Metastasis through Acetylation-Dependent Stabilization of Snail.
    Qin ZY; Wang T; Su S; Shen LT; Zhu GX; Liu Q; Zhang L; Liu KW; Zhang Y; Zhou ZH; Zhang XN; Wen LZ; Yao YL; Sun WJ; Guo Y; Liu KJ; Liu L; Wang XW; Wei YL; Wang J; Xiao HL; Liu P; Bian XW; Chen DF; Wang B
    Cancer Res; 2019 Oct; 79(19):4869-4881. PubMed ID: 31311807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MYC protein stability is negatively regulated by BRD4.
    Devaiah BN; Mu J; Akman B; Uppal S; Weissman JD; Cheng D; Baranello L; Nie Z; Levens D; Singer DS
    Proc Natl Acad Sci U S A; 2020 Jun; 117(24):13457-13467. PubMed ID: 32482868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bromodomain protein BRD4 promotes cell proliferation in skin squamous cell carcinoma.
    Xiang T; Bai JY; She C; Yu DJ; Zhou XZ; Zhao TL
    Cell Signal; 2018 Jan; 42():106-113. PubMed ID: 29050985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic targeting of BET bromodomain protein, Brd4, delays cyst growth in ADPKD.
    Zhou X; Fan LX; Peters DJ; Trudel M; Bradner JE; Li X
    Hum Mol Genet; 2015 Jul; 24(14):3982-93. PubMed ID: 25877301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1.
    Zhang C; Su ZY; Wang L; Shu L; Yang Y; Guo Y; Pung D; Bountra C; Kong AN
    Biochem Pharmacol; 2016 Oct; 117():35-45. PubMed ID: 27520485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells.
    Otto C; Schmidt S; Kastner C; Denk S; Kettler J; Müller N; Germer CT; Wolf E; Gallant P; Wiegering A
    Neoplasia; 2019 Nov; 21(11):1110-1120. PubMed ID: 31734632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JQ1, an inhibitor of the epigenetic reader BRD4, suppresses the bidirectional MYC-AP4 axis via multiple mechanisms.
    Choi SK; Hong SH; Kim HS; Shin CY; Nam SW; Choi WS; Han JW; You JS
    Oncol Rep; 2016 Feb; 35(2):1186-94. PubMed ID: 26573731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic Targeting of Histone H3K27 Acetylation/BRD4-dependent Induction of ALDH1A3 for Early-phase Drug Tolerance of Gastric Cancer.
    Lee J; Mashima T; Kawata N; Yamamoto N; Morino S; Inaba S; Nakamura A; Kumagai K; Wakatsuki T; Takeuchi K; Yamaguchi K; Seimiya H
    Cancer Res Commun; 2024 May; 4(5):1307-1320. PubMed ID: 38669046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.